These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Analysis of the treatment method in patients with COPD].
    Author: Lubiński W, Toczyska I, Rozyńska R, Chciałowski A.
    Journal: Pol Merkur Lekarski; 2003 Dec; 15(90):547-50. PubMed ID: 15058259.
    Abstract:
    UNLABELLED: According the mass spirometry, every third person over forty years old, suffer from COPD in Poland. Prophylaxis, early detection and proper treatment are necessary for the limitation of group of patients with severe COPD in the future. We analyzed the usage of particular group of medicines and estimated conformability of COPD treatment with actual recommendations. MATERIAL AND METHODS: We included 125 subjects--26% women (n = 33), and 74% men (n = 92). Mean age was 62 +/- 10. Current smokers were 46% (n = 58) with mean time of smoking was 28 +/- 14 pack-years, ex-smokers 41% (n = 51), non-smokers 13% (n = 16). We recorded the treatment way and HbCO level in expired air. Spirometry and flow-volume test were provided. We used Statistica program for results statistical analysis. RESULTS: Usually, patients with mild COPD are treated with theophilline (49%), long-acting beta 2-agonists (40%), short-acting beta 2-agonists (35%), inhaled steroids and anticholinergics (24%). In mild-severe and severe form of COPD are used: theophilline (50%), short-acting beta 2-agonists (40%), long-acting beta 2-agonists (27%), inhaled steroids (19%) and anticholinergics (12%). 8.1 subjects with mild, 1.7% with mild-severe and 5.5% with severe COPD are treated with recommended connection of anticholinergic and long-acting beta 2-agonist. CONCLUSIONS: Mostly theophilline and short-acting beta 2-agonists are used. Anticholinergics are used too seldom. COPD treatment is insufficient and inconsistent with actual recommendations. Only 1.7 to 5.5% patients are treated with recommended combination of anticholinergic and long-acting beta 2-agonist.
    [Abstract] [Full Text] [Related] [New Search]